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hronic B-cell lymphocytic leukemia (B-CLL) represents 0.9%
f all new cancers. It is estimated that there will be almost
5 000 new cases and 4600 deaths due to CLL in 2015 in the
SA.1 The median ages at diagnosis and death are 71 years and
0 years, respectively.1 The criteria that deﬁne the diagnosis of
-CLL include the presence of at least 5 × 106 B lymphocytes/L
ith the peculiar CLL phenotype, persisting in the peripheral
lood for at least 3 months.2
Monoclonal B-cell lymphocytosis (MBL) is characterized by
n expansion of circulating clonal B lymphocytes, totaling
ess than 5 × 109/L in individuals without any symptoms or
igns of a lymphoproliferative disease.3,4 Three categories of
BL  have been recognized: CLL-like MBL, atypical CLL-MBL,
nd CD5-negative MBL. Seventy-ﬁve percent of all cases are
LL-like MBL, and present the same phenotype as CLL (CD5,
D19, CD23 and CD20dim, with low surface immunoglobulin
xpression).3,4 Moreover, the clonal B cells in CLL-like MBL
hare similar chromosomal abnormalities with B-CLL.
A recent systematic review reported frequencies of MBL
anging from <1% to 18.2%.5 This wide variation reﬂects dif-
erent study populations (general population, blood donor
opulation, outpatients from clinics and relatives of CLL
atients – familial cases or sporadic cases) and the sensitivity
f the multiparameter ﬂow cytometry employed (two or three
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eserved.color antibody-ﬂuorochrome combinations or four to eight
color antibody-ﬂuorochrome combinations). Furthermore, it
is well established that the prevalence increases with age. In a
recent study in Spain, 608 healthy individuals were evaluated
with an eight-color antibody panel. The overall prevalence of
MBL  was 14%; it was around 5% in under 60-year-old indi-
viduals, 17.5% in individuals between 60 and 69 years old,
and reached 75% in ages >89 years.6 High frequencies of MBL
(12–18%) have been observed among ﬁrst-degree relatives of
familial CLL patients, deﬁned as a family with at least two
ﬁrst-degree relatives with CLL. However, long-term follow-up
studies of the MBL individuals identiﬁed among relatives of
familial CLL patients are still lacking.7,8
MBL can be further classiﬁed as ‘high-count MBL’  or ‘low-
count MBL’ depending on the number of circulating B cells (the
size of the clone). One accepted cut-off to distinguish between
these two categories is 5 × 109/L clonal B cells.4,9 High-count
MBL  is also called ‘clinical MBL’ because it is often detected
during an investigation of lymphocytosis. The median number
of B cells is around 3 × 109/L, and 95% of the cases present more
than 4.5 × 109 lymphocytes/L. The risk of progression to CLL isl do Rio de Janeiro (UFRJ), Rua Professor Paulo Rocco, 255, 4.andar,
around 1% per year. In contrast, in low-count MBL  almost
95% of the cases have less than 1.0 × 109/L clonal B cells and
have a low risk of progression to CLL.11 Of note, this condition
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lymphocytosis in individuals from sporadic (non-familial)
chronic lymphocytic leukemia families persists over time, but286  rev bras hematol hem
is rarely found in the clinical practice, since high-sensitivity
techniques are required for its detection.9
Some authors have argued that low-count MBL might not
be an actual pre-leukemic state, reﬂecting instead immune
senescence or persistent antigen stimulation. One study, in
particular, compared the immunogenetic proﬁle of low-count
and high-count CLL-like MBL  with early stage CLL (Rai stage 0).
They found that high-count MBL  was similar to CLL Rai stage
0, while low-count MBL  was not.12
Although virtually all CLL cases evolve from CLL-like MBL,13
not every individual with CLL-like MBL  has the same risk of
progression to CLL. So far, the number of clonal B lympho-
cytes is the only well-established factor correlated with the
likelihood of transformation to CLL.9 Two studies showed that
B-cell counts at presentation below 1.2 × 109 or 1.9 × 109/L pre-
dicted a stable course, while counts over 3.7 × 109/L predicted
rising lymphocyte numbers over time.14,15 Further studies are
needed to determine other biological factors associated with
a higher risk of progression.9
In their ﬁrst report in 2009, while studying 167 ﬁrst-degree
relatives of sporadic (non-familial) CLL patients, Matos et al.
reported an overall prevalence of 4.1%, reaching 15.6% in over
60-year-old individuals.16 The authors suggested that, as the
prevalence in older relatives of sporadic CLL patients was sim-
ilar to that reported among relatives of familial CLL patients,
the risk of MBL  might be similar and also susceptibility for the
development of CLL. In the present study, the authors have
analyzed the long-term outcome of ﬁve out of the seven indi-
viduals with MBL.17 All had presented with low-count MBL.
After a median follow-up of 7.6 years, no progression to CLL
was observed, and the size of the clones remained stable.
These results are in line with previous studies in CLL-like MBL
detected in the general population.
In conclusion, current evidence does not support system-
atic laboratory monitoring of low-count MBL individuals to
detect progression; clinical and laboratory monitoring is only
recommended in high-count MBL. Also for the latter group,
open questions remain regarding biological factors that could
predict the risk of progression, and whether its distinction
from CLL Rai stage 0 based on the arbitrary threshold of
5 × 109/L has any biological or clinical signiﬁcance.
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